title: [Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit].
abstract: OBJECTIVE
  To establish a HPLC method for measuring tashinone II(A) concentration in rabbit plasma and study the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles and tashinone II(A) injection in rabbits.
  
  
  METHODS
  A single dose of TS-PLA-NP and TS II(A) injection was administered to 8 healthy rabbits via the ear-edge vein, at the set time withdrew the blood and prepared. The concentrations of tashinone II(A) in plasma were measured by HPLC with gemfibrozil as the internal standard. The pharmacokinetic parameters of TS-PLA-NP and tashinone II(A) injection were calculated by program DAS2.0.
  
  
  RESULTS
  The average retention times of gemfibrozil and tashinone II(A) were 10.5 and 14.5 min, respectively. The half-life was prolonged from 2. 573 h of free tashinone II(A) to 4. 117 h and MRT(0-infinity) from 2.585 h to 6.033 h. The max concentration of tashinone II(A) was reduced from 0.21 to 0.134 mg/L.
  
  
  CONCLUSIONS
  The method for the pharmacokinetic research of tshinone II A in rabbit plasma is accuracy, rapid and sensitive. TS-PLA-NP shows significant characteristic of delayed-release.
authors.affiliation: Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. bw0999@hotmail.com
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Nian-Ping
authors.initials: NP
authors.lastname: Feng
authors.forename: Yi-Lei
authors.initials: YL
authors.lastname: Nan
authors.forename: Li-Hong
authors.initials: LH
authors.lastname: Zhong
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Chen
authors.forename: Zhong-Zhe
authors.initials: ZZ
authors.lastname: Fan
authors.forename: Qi
authors.initials: Q
authors.lastname: Li
mesh_terms: D045784:Abietanes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D019540:Area Under Curve; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism*; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D009368:Neoplasm Transplantation; D010316:Particle Size; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry*; D011817:Rabbits; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D045784:Abietanes; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D011108:Polymers; C021751:tanshinone